Ibvilda M 500 Tablet is a combination oral antihyperglycemic agent containing Metformin 500 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, thereby enhancing glucose uptake and utilization. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the levels of incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. The synergistic action of these two agents helps achieve better glycemic control by targeting multiple pathophysiological defects in type 2 diabetes. Ibvilda M 500 is typically prescribed as an adjunct to diet and exercise when monotherapy with either agent is insufficient to achieve adequate glycemic control. It is important to monitor renal function prior to and during treatment, as Metformin is contraindicated in patients with significant renal impairment. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often subside with continued use. Patients should be advised regarding the risk of hypoglycemia, particularly when used in combination with other antidiabetic agents. Regular monitoring of blood glucose levels and adherence to lifestyle modifications are essential for optimal therapeutic outcomes.